Press Releases

Date Title
May 12, 2016
Oncobiologics Announces Pricing of Its Initial Public Offering of Units
CRANBURY, N.J. , May 12, 2016 /PRNewswire/ --  Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced the pricing of its initial public offering of
December 14, 2015
Oncobiologics Expands Its Board Of Directors With The Appointment Of Three New Independent Members
Oncobiologics Expands its Board of Directors with the Appointment of Three New Independent Members Cranbury, NJ – December 14, 2015 — Oncobiologics, Inc. (Oncobiologics) announces the expansion of its Board of Directors with the appointment of Albert D. Dyrness, Kurt J.
October 5, 2015
ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial
Oncobiologics Announces ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial Cranbury, NJ – Oct. 5, 2015 — Oncobiologics, Inc. (“Oncobiologics”) announced that its bevacizumab (Avastin®) biosimilar candidate, ONS-1045, met the primary and
September 29, 2015
Oncobiologics Secures Financing from Sabby Management, LLC
Oncobiologics Secures Financing from Sabby Management, LLC to Advance BioSymphony TM Platform and Monoclonal Antibody Biosimilars Pipeline Cranbury, NJ – Sept. 29, 2015 — Oncobiologics, Inc. (“Oncobiologics”) announced that it closed an additional round of financing with Sabby Management, LLC.
September 16, 2015
Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officer
Oncobiologics, Inc. announced the appointment of Lawrence A. Kenyon as its Chief Financial Officer (CFO), effective September 15, 2015. Mr. Kenyon is an accomplished executive with extensive experience managing the financial and business operations of emerging and established private and public
July 27, 2015
Oncobiologics Secures $31 Million Financing
Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing.  Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs.
July 2, 2015
Noted Immunology Expert Joins Oncobiologics as Chief Medical Officer
June 2015 - Cranbury, New Jersey — Kenneth Bahrt, MD, FACR has joined Oncobiologics as its Chief Medical Officer.  A recognized expert in immunology, he brings over 30 years of clinical and pharmaceutical industry experience in both small molecule and protein therapeutics.    Oncobiologics Founder
May 4, 2015
Oncobiologics opens commercial launch manufacturing facility
Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing monoclonal antibody (mAb) biosimilars,has completed the construction of its GMP commercial launch manufacturing facility at its headquarters in Cranbury, New Jersey.
April 15, 2015
Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin® biosimilar) candidate
Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development for ONS-1045, an Avastin®/bevacizumab biosimilar candidate, is underway with dosing completed in its pivotal pharmacokinetic (PK) study.  This study is
February 12, 2015
ONS-3010 (Humira®/adalimumab biosimilar) meets primary endpoints in first clinical study
Cranbury, NJ – February 12, 2015 — Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars,announced today that ONS-3010, its adalimumab (Humira®) biosimilar candidate met the primary endpoints in its first clinical study.
Displaying 31 - 40 of 46